A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/13/2011	US8076319 Treatment of conditions relating to hormone deficiencies by administration of progestins
12/13/2011	US8076318 Caged ligands and uses thereof
12/13/2011	US8076317 administering contraceptives comprising hormones in cycles
12/13/2011	US8076316 Steroid compounds and formulations
12/13/2011	US8076315 Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
12/13/2011	US8076314 Topical compositions for anti-aging and methods of using same
12/13/2011	US8076313 Composition containing fermentable polysaccharides
12/13/2011	US8076312 Use of lipid conjugates in the treatment of disease
12/13/2011	US8076311 Compositions and methods for modulating the immune system
12/13/2011	US8076310 Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
12/13/2011	US8076306 Compositions and their uses directed to hepcidin
12/13/2011	US8076303 Nucleotide and oligonucleotide prodrugs
12/13/2011	US8076302 Pyrimidine nucleoside derivatives and salts thereof
12/13/2011	US8076301 10-substituted macrolide antibiotics
12/13/2011	US8076100 Genetic engineering; vaccine; induction antibodies
12/13/2011	US8076098 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
12/13/2011	US8076073 Cholesterol and hedgehog signaling
12/13/2011	US8076071 Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
12/13/2011	US8076066 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
12/13/2011	US8075923 Use of hederagenin 3-O-α-L-rhamnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4)-α-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors
12/13/2011	US8075917 Composition for solubilization of paclitaxel and preparation method thereof
12/13/2011	US8075914 Controlled release melatonin
12/13/2011	US8075913 Method of producing a cationic liposomal preparation comprising a lipophilic compound
12/13/2011	US8075912 Autodestructive transdermal therapeutic system
12/13/2011	US8075911 Transparent transdermal nicotine delivery devices
12/13/2011	US8075908 Apparatus and method for reducing the occurrence of post-surgical adhesions
12/13/2011	US8075903 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
12/13/2011	US8075902 Diagnosis and treatment of cancer related to human dormancy
12/13/2011	US8075892 Treatment with anti-ErbB2 antibodies
12/13/2011	US8075874 Methods for disinfecting and removing smear layer from tooth surfaces
12/13/2011	US8075873 Method of preparing dry powder inhalation compositions
12/13/2011	US8074644 Method of forming an aerosol for inhalation delivery
12/13/2011	DE202010017303U1 Trockenverarbeitung von Retigabin Dry processing of retigabine
12/13/2011	CA2656005C Chemotherapeutic compounds for selectively targeting tumor cells with fr type receptors
12/13/2011	CA2634769C Nitrogen-containing bicyclic heteroaryl compounds and methods of use
12/13/2011	CA2600832C Hiv integrase inhibitors
12/13/2011	CA2593492C Methods and compositions for decreasing saliva production
12/13/2011	CA2559224C Drug delivery system based on polyethylene vinylacetate copolymers
12/13/2011	CA2554024C A stable solution containing beside water either (6s)-sodium-folinate or (6s)-potassium-folinate in an amount from 2% by weight to 6% by weight
12/13/2011	CA2541618C Rsv polymerase inhibitors
12/13/2011	CA2539070C Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
12/13/2011	CA2530938C Compounds, formulations, and methods for treating or preventing rosacea
12/13/2011	CA2528642C Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
12/13/2011	CA2517572C Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
12/13/2011	CA2512618C Use of r-4-trimethylammonio-3-(tetradecyl-carbamoyl)-aminobutyrate and metformin for the treatment of diabetes
12/13/2011	CA2503396C Water-soluble meloxicam granules
12/13/2011	CA2502528C 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia
12/13/2011	CA2502297C Compounds for the treatment of metabolic disorders
12/13/2011	CA2496139C Benzimidazole derivatives
12/13/2011	CA2494628C Acylated arylcycloalkylamines and their use as pharmaceuticals
12/13/2011	CA2492287C Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
12/13/2011	CA2482114C Solid dosage form comprising caffeine
12/13/2011	CA2476008C Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
12/13/2011	CA2464420C Dosage unit comprising a prostaglandin analog for treating constipation
12/13/2011	CA2452806C Water-soluble stabilized self-assembled polyelectrolytes
12/13/2011	CA2450448C Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same
12/13/2011	CA2449578C Pyrrolidine oxadiazole- and thiadiazole derivatives
12/13/2011	CA2425316C A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
12/13/2011	CA2392666C Dextrin containing compositions for prevention of adhesions
12/13/2011	CA2386954C Methods of treating vascular diseases characterized by nitric oxide insufficiency
12/13/2011	CA2229203C Antigenic preparations from keratinophilic fungi
12/09/2011	CA2802767A1 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
12/08/2011	WO2011153514A2 The use of inhibitors of bruton's tyrosine kinase (btk)
12/08/2011	WO2011153513A2 Nanoemulsion composition containing vitamin k
12/08/2011	WO2011153509A1 Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
12/08/2011	WO2011153502A2 Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them
12/08/2011	WO2011153495A1 Cancer treatment with wortmannin analogs
12/08/2011	WO2011153493A2 Biodegradable lipids for the delivery of active agents
12/08/2011	WO2011153444A1 New forms of rifaximin and uses thereof
12/08/2011	WO2011153435A1 Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
12/08/2011	WO2011153433A1 Spla2 inhibitor conjugate compounds and methods of use
12/08/2011	WO2011153429A2 Methods of treatment
12/08/2011	WO2011153396A1 Hepatitis c virus inhibitors
12/08/2011	WO2011153383A1 Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
12/08/2011	WO2011153382A1 Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and platinum compound
12/08/2011	WO2011153374A1 Prodrugs of azacitidine 5'-phosphate
12/08/2011	WO2011153368A1 Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
12/08/2011	WO2011153365A1 Phosphaplatins and their use for treatment of cancers
12/08/2011	WO2011153359A1 Glycine transporter-1 inhibitors, methods of making them, and uses thereof
12/08/2011	WO2011153353A1 Tocopherol derivatives and methods of use
12/08/2011	WO2011153331A2 Optical sensor conjugates for detecting reactive oxygen and/or reactive nitrogen species in vivo
12/08/2011	WO2011153327A1 Methods of treating hepatic encephalopathy
12/08/2011	WO2011153319A1 C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
12/08/2011	WO2011153315A1 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
12/08/2011	WO2011153247A1 Combination therapies
12/08/2011	WO2011153221A1 Solid state forms of ixabepilone
12/08/2011	WO2011153206A1 Processes for the preparation of 5-ht2c receptor agonists
12/08/2011	WO2011153199A1 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
12/08/2011	WO2011153197A1 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
12/08/2011	WO2011153192A2 Cytochrome p450 inhibitors and uses thereof
12/08/2011	WO2011153157A2 Benzoquinolone inhibitors of vmat2
12/08/2011	WO2011153136A1 Organic compounds
12/08/2011	WO2011153135A1 Organic compounds
12/08/2011	WO2011153049A1 Methods and use of compounds that bind to her2/neu receptor complex
12/08/2011	WO2011153010A1 Methods of treatment of pancreatic cancer
12/08/2011	WO2011153009A1 Methods of treating bladder cancer
12/08/2011	WO2011152886A2 Malodor neutralizing compositions comprising undecylenic acid or citric acid
12/08/2011	WO2011152869A1 Oral formulations of bipolar trans carotenoids
12/08/2011	WO2011152810A1 Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
12/08/2011	WO2011152809A2 Effervescent formulations comprising cephalosporin and clavulanic acid

1 ... 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 ... 7860